Arixtra cleared in EU for superficial vein thrombosis
30 September 2010
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
Alchemia gets milestone on fondaparinux
22 December 2008
EMEA OKs Arixtra for UA/STEMI and STEMI
10 September 2007
Competition in the venous thromboembolism market
20 August 2007
Japan's Chuikyo adds 13 NCEs to NHI list
18 June 2007
GSK's Arixtra and Seretide/Advair approved in Japan
23 April 2007
GSK's Arixtra gets FDA approvable letter
12 February 2007
GSK's Arixtra gets fast tracked by US FDA
16 October 2006
GSK's Arixtra superior to standard ACS therapy
20 March 2006
GSK's Arixtra "cuts VTE risk 47%," ARTEMIS study
20 February 2006
Arixtra halves major bleeding in ACS
12 September 2005
GSK'a Arixtra cleared in EU
18 July 2005
EC clears GSK's Arixtra for prevention of VTE
14 February 2005
Adolor forms alliance with GSK for Arixtra
10 January 2005
GSK buys drugs and site from Sanofi-Aventis
13 September 2004
Sanofi's bid for Aventis cleared by FTC
2 August 2004
Sanofi to sell Aventis' Campto to Pfizer
5 July 2004
Arixtra approved for two new indications
14 June 2004
FTC seeks more info on Sanofi-Aventis
10 May 2004
More reactions to Sanofi's hostile bid for Aventis
2 February 2004
Sanofi-Synthelabo's 2003 sales up 15.6%
26 January 2004
Stock Commentary - Europe
19 January 2004
Sanofi acquires Arixtra from Organon
19 January 2004
New data for Arixtra in treatment of PE
10 November 2003
Stock Commentary - Europe
10 November 2003
Akzo Nobel pharma under pressure
27 October 2003
Sanofi sales strong but below expectations
27 October 2003
Sanofi-Synthelabo ups forecast on strong 1st-half, but fears persist over key patent
8 September 2003
Arixtra prevents VTE in surgery patients
28 July 2003
Stock Commentary - Europe
28 July 2003
Arixtra lowers risk of VTE in acutely ill
21 July 2003
Akzo shares slump on negative newsflow
7 July 2003
New use for Sanofi/ Organon's Arixtra
30 June 2003
Stock Commentary - Europe
30 June 2003
Akzo Nobel 1st qtr earnings plunge 30%
28 April 2003
Fast-track review for Arixtra sNDA in USA
10 March 2003
Aventis sued for alleged US anticoagulant monopoly
10 March 2003
Akzo Nobel pharma unit
17 February 2003
2002's crop of new product launches backs up R&D fears
10 February 2003
Anticoagulant market to triple by 2011
24 June 2002
Akzo set to break record level profits
29 April 2002
Arixtra gets EU OK
1 April 2002
Sanofi-Synthelabo 2001 EPS leap 44%
25 February 2002
Update: Akzo and Sanofi-Synthelabo's Arixtra debuts in USA for DVT
18 February 2002
Stock Commentary - Europe
28 January 2002
Arixtra gets EU backing after US approval
7 January 2002
Arixtra gets EU backing after US approval
14 December 2001
New antithrombotic Arixtra cleared in USA
13 December 2001
New antithrombotic Arixtra approved in USA
10 December 2001
Akzo planning Arixtra launch in January?
28 November 2001
Sanofi Arixtra investment
15 November 2001
Arixtra "at least as good" as LMWH in angina
15 November 2001
Arixtra studies support superiority to LMWH
5 November 2001
France's Sanofi-Synthelabo continues to outperform competitors
26 October 2001
Akzo Nobel predicts double-digit pharma growth for 2001
10 October 2001
Sanofi-Synthelabo first-half net income rises 50% - UPDATE
6 September 2001
Stock Commentary - Europe
6 September 2001
Stock Commentary - Europe
30 August 2001
Stock Commentary - Europe
16 August 2001
Arixtra tops LMWH in meta-analysis
11 July 2001
Sanofi-Synthelabo profits to rise 30%
24 May 2001
FDA grants fast track review to Arixtra
27 April 2001
Showing 1-80 of 80 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
